Metastatic spread in patients with non-small cell lung cancer is associated with a reduced density of tumor-infiltrating T cells
- 759 Downloads
Tumor-infiltrating lymphocytes play an important role in cell-mediated immune destruction of cancer cells and tumor growth control. We investigated the heterogeneity of immune cell infiltrates between primary non-small cell lung carcinomas (NSCLC) and corresponding metastases. Formalin-fixed, paraffin-embedded primary tumors and corresponding metastases from 34 NSCLC patients were analyzed by immunohistochemistry for CD4, CD8, CD11c, CD68, CD163 and PD-L1. The percentage of positively stained cells within the stroma and tumor cell clusters was recorded and compared between primary tumors and metastases. We found significantly fewer CD4+ and CD8+ T cells within tumor cell clusters as compared with the stromal compartment, both in primary tumors and corresponding metastases. CD8+ T cell counts were significantly lower in metastatic lesions than in the corresponding primary tumors, both in the stroma and the tumor cell islets. Of note, the CD8/CD4 ratio was significantly reduced in metastatic lesions compared with the corresponding primary tumors in tumor cell islets, but not in the stroma. We noted significantly fewer CD11c+ cells and CD68+ as well as CD163+ macrophages in tumor cell islets compared with the tumor stroma, but no difference between primary and metastatic lesions. Furthermore, the CD8/CD68 ratio was higher in primary tumors than in the corresponding metastases. We demonstrate a differential pattern of immune cell infiltration in matched primary and metastatic NSCLC lesions, with a significantly lower density of CD8+ T cells in metastatic lesions compared with the primary tumors. The lower CD8/CD4 and CD8/CD68 ratios observed in metastases indicate a rather tolerogenic and tumor-promoting microenvironment at the metastatic site.
KeywordsNon-small cell lung cancer Primary tumor Metastasis Immune cells Anti-tumor immunity
Non-small cell lung cancer
This work was supported by grants from the Swiss National Science Foundation, the Wilhelm Sander-Foundation, the Cancer League Basel, the Huggenberger-Bischoff Foundation for Cancer Research, the Research Fonds of the University Basel and the Freiwillige Akademische Gesellschaft Basel.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 5.Audia S, Nicolas A, Cathelin D et al (2007) Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes. Clin Exp Immunol 150:523–530. doi:10.1111/j.1365-2249.2007.03521.x PubMedPubMedCentralCrossRefGoogle Scholar
- 17.Villegas FR, Coca S, Villarrubia VG, Jiménez R, Chillón MJ, Jareño J, Zuil M, Callol L (2002) Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 35:23–28. doi:10.1016/S0169-5002(01)00292-6 PubMedCrossRefGoogle Scholar
- 35.Martin K, Müller P, Schreiner J, Prince SS, Lardinois D, Heinzelmann-Schwarz VA, Thommen DS, Zippelius A (2014) The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity. Cancer Immunol Immunother 63:925–938. doi:10.1007/s00262-014-1565-4 PubMedCrossRefGoogle Scholar
- 36.Zhang W, Guo N, Yu C, Wang H, Zhang Y, Xia H, Yu J, Lu J (2012) Differential expression of ERCC-1 in the primary tumors and metastatic lymph nodes of patients with non-small cell lung cancer adenocarcinoma. Tumour Biol 33:2209–2216. doi:10.1007/s13277-012-0482-4 PubMedPubMedCentralCrossRefGoogle Scholar
- 37.Shimizu K, Yukawa T, Hirami Y, Okita R, Saisho S, Maeda A, Yasuda K, Nakata M (2013) Heterogeneity of the EGFR mutation status between the primary tumor and metastatic lymph node and the sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancer. Target Oncol 8:237–242. doi:10.1007/s11523-012-0241-x PubMedCrossRefGoogle Scholar
- 45.Zitvogel L, Kepp O, Aymeric L, Ma Y, Locher C, Delahaye NF, André F, Kroemer G (2010) Integration of host-related signatures with cancer cell-derived predictors for the optimal management of anticancer chemotherapy. Cancer Res 70:9538–9543. doi:10.1158/0008-5472.CAN-10-1003 PubMedCrossRefGoogle Scholar